Investing

Aclaris Therapeutics : ACRS

ACRS

Stock Data

$4.50

$0.08 (1.81%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a line of novel small molecule therapeutics to address the needs of patients with immuno-inflammatory diseases. The company is headquartered in Wayne, Pennsylvania.

All Aclaris Therapeutics Articles

4 Articles

Lee Jackson | Jan 30, 2026 at 7:59 AM EST

Here Are Friday’s Top Wall Street Analyst Research Calls: Broadcom, Circle Internet, Kenvue, Medtronic, Sandisk, Southwest Airlines, Spotify, and More

Pre-Market Stock Futures: Futures are trading lower as we prepare to close out the trading week. What a difference a…

Chris Lange | Jun 15, 2021 at 9:11 AM EDT

Tuesday Analyst Upgrades and Downgrades: Campbell Soup, Exact Sciences, Exelixis, Spirit Airlines, Sarepta, ZTO and More

Tuesday’s top analyst upgrades and downgrades included Campbell Soup, Exact Sciences, Exelixis, Pool, Spirit Airlines and ZTO Express.

Chris Lange | Apr 21, 2021 at 12:10 PM EDT

BP, Conagra, Mattel, Pepsi, UnitedHealth and More Wednesday Afternoon Analyst Calls

24/7 Wall St. looks at some big analyst calls that we have seen so far on Wednesday, including BP, Conagra…

Chris Lange | Jan 19, 2021 at 10:44 AM EST

Is Aclaris Therapeutics a Stock to Buy After Nearly 200% Run-Up and Now This?

Aclaris shares more than doubled to start out the week after the company announced positive results from its mid-stage rheumatoid…